LVTX Fundamental Analysis - LAVA THERAPEUTICS NV

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to LVTX. LVTX was compared to 551 industry peers in the Biotechnology industry. While LVTX seems to be doing ok healthwise, there are quite some concerns on its profitability. LVTX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LVTX has reported negative net income.

In the past 5 years LVTX always reported negative net income.

LVTX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

LVTX has a worse Return On Assets (-69.12%) than 63.16% of its industry peers.

LVTX has a worse Return On Equity (-190.76%) than 66.79% of its industry peers.

		Industry Rank	Sector Rank
ROA	-69.12%
ROE	-190.76%
ROIC	N/A

ROA(3y)-31.44%

ROA(5y)-40.51%

ROE(3y)-69.63%

ROE(5y)-90.26%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

LVTX has a Gross Margin of 100.00%. This is amongst the best in the industry. LVTX outperforms 99.64% of its industry peers.

LVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	100%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, LVTX has about the same amount of shares outstanding.

Compared to 5 years ago, LVTX has more shares outstanding

The debt/assets ratio for LVTX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -4.52, we must say that LVTX is in the distress zone and has some risk of bankruptcy.

LVTX's Altman-Z score of -4.52 is in line compared to the rest of the industry. LVTX outperforms 42.11% of its industry peers.

LVTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.52

ROIC/WACCN/A

WACC7%

2.3 Liquidity

LVTX has a Current Ratio of 6.73. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.

LVTX's Current ratio of 6.73 is fine compared to the rest of the industry. LVTX outperforms 64.97% of its industry peers.

LVTX has a Quick Ratio of 6.73. This indicates that LVTX is financially healthy and has no problem in meeting its short term obligations.

LVTX has a Quick ratio of 6.73. This is in the better half of the industry: LVTX outperforms 65.34% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.73
Quick Ratio	6.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LVTX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.70%.

The Revenue has decreased by -4.43% in the past year.

Measured over the past years, LVTX shows a very strong growth in Revenue. The Revenue has been growing by 33.82% on average per year.

EPS 1Y (TTM)3.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-550%

Revenue 1Y (TTM)-4.43%

Revenue growth 3Y33.82%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, LVTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.54% on average per year.

LVTX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.

EPS Next Y-25.4%

EPS Next 2Y10.84%

EPS Next 3Y16.82%

EPS Next 5Y11.54%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

LVTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year LVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LVTX's earnings are expected to grow with 16.82% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.84%

EPS Next 3Y16.82%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LVTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LAVA THERAPEUTICS NV

NASDAQ:LVTX (8/5/2025, 5:52:56 PM)

After market: 1.52 +0.02 (+1%)

1.505

+0.03 (+2.38%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-14 2025-05-14/bmo

Earnings (Next)08-26 2025-08-26

Inst Owners36.96%

Inst Owner Change0%

Ins Owners0.17%

Ins Owner Change0%

Market Cap39.60M

Analysts78

Price Target1.87 (24.25%)

Short Float %0.29%

Short Ratio1.59

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)60.08%

Min EPS beat(2)53.47%

Max EPS beat(2)66.68%

EPS beat(4)3

Avg EPS beat(4)24.77%

Min EPS beat(4)-36.66%

Max EPS beat(4)66.68%

EPS beat(8)6

Avg EPS beat(8)15.96%

EPS beat(12)10

Avg EPS beat(12)26.68%

EPS beat(16)14

Avg EPS beat(16)24.89%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)32.01%

EPS NY rev (1m)-2.69%

EPS NY rev (3m)25.27%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.3
P/FCF	N/A
P/OCF	N/A
P/B	1.54
P/tB	1.54
EV/EBITDA	N/A

EPS(TTM)-1.04

EYN/A

EPS(NY)-0.72

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0.46

BVpS0.98

TBVpS0.98

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-69.12%
ROE	-190.76%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	100%
FCFM	N/A

ROA(3y)-31.44%

ROA(5y)-40.51%

ROE(3y)-69.63%

ROE(5y)-90.26%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.73
Quick Ratio	6.73
Altman-Z	-4.52

F-ScoreN/A

WACC7%

ROIC/WACCN/A

Cap/Depr(3y)66.67%

Cap/Depr(5y)88.88%

Cap/Sales(3y)4.68%

Cap/Sales(5y)8.7%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)3.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-550%

EPS Next Y-25.4%

EPS Next 2Y10.84%

EPS Next 3Y16.82%

EPS Next 5Y11.54%

Revenue 1Y (TTM)-4.43%

Revenue growth 3Y33.82%

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-14.87%

EBIT growth 1Y-82.9%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-1.37%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y52.29%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y51.48%

OCF growth 3YN/A

OCF growth 5YN/A

LAVA THERAPEUTICS NV (LVTX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens